

13 October 2023

Our Ref: RFI 53612

Dear

**Freedom of Information Act 2000
Information in Relation to the Treatment of Hidradenitis Suppurativa (HS).**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 19 September 2023.

A response to each of the questions raised has been provided by the Surgery, Elective, Maternity & Paediatrics Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Caroline Degans
Information Governance Officer

Q1. Could you please tell me how many patients were treated in the last 3 months for Hidradenitis Suppurativa (HS) with the following biologic drugs:

A1. Please Table 1 for the number of patients who were treated for Hidradenitis Suppurativa (HS) for the period 01/06/2023 to 31/08/2003.

Table 1

Treatment	Number of Patients Treated
Adalimumab - Humira	4
Adalimumab Biosimilar	31
Bimekizumab	Nil
Certolizumab	Nil
Infliximab - Remicade	2
Infliximab Biosimilar	3
Secukinumab	Nil
Ustekinumab	Nil